National Specialised Hospital For Active Treatment Of Haematological Diseases
- Address
- lock Available on a paid plan
National Specialised Hospital For Active Treatment Of Haematological Diseases
A leading specialized center dedicated to the comprehensive treatment and clinical research of blood disorders and haematological malignancies. The facility demonstrates particular expertise in investigating novel therapeutic approaches for both benign and malignant haematological conditions, with a strong focus on improving patient outcomes through participation in international multi-center clinical trials.
- Haematological malignancies including Diffuse Large B-Cell Lymphoma (DLBCL) with advanced immunotherapy and combination treatment protocols
- Inherited blood disorders such as thalassemia, evaluating innovative therapies for both transfusion-dependent and non-transfusion-dependent disease variants
- Immune-mediated blood disorders including Primary Immune Thrombocytopenia (ITP) utilizing cutting-edge immunomodulatory treatments
- Supportive care research addressing cancer-related complications such as cachexia in haematological and solid tumor patients
The hospital's research portfolio encompasses a broad spectrum of interventions, from targeted biological agents and bispecific antibodies to novel metabolic modulators and immunotherapy combinations. This comprehensive approach positions the center at the forefront of haematological disease management, bridging the gap between basic science discoveries and clinical applications while providing patients access to potentially life-changing experimental therapies within rigorous research frameworks.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Argenx1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in National Specialised Hospital For Active Treatment Of Haematological Diseases
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Efgartigimod Alfa in Adults with Primary Immune Thrombocytopenia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Argenx | Phase III | Recruiting | Feb 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Epcoritamab | 2 | Unknown | 2023-01-26 | 2024-09-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.